fludarabine has been researched along with Nausea in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC | 1 |
Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A | 1 |
Atkins, JN; Bengtson, EM; Byrd, JC; Donohue, KA; Hoke, EE; Larson, RA; Lin, TS; Link, BK; Lucas, MS; Rai, KR | 1 |
Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J | 1 |
Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R | 1 |
Busch, R; Eichhorst, BF; Hallek, M; Herschbach, P; Kuhn-Hallek, I; Obwandner, T | 1 |
6 trial(s) available for fludarabine and Nausea
Article | Year |
---|---|
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Nausea; Quality of Life; Surveys and Questionnaires; Vidarabine; Vomiting | 2007 |
2 other study(ies) available for fludarabine and Nausea
Article | Year |
---|---|
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting | 2018 |
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |